Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-018603
Filing Date
2016-05-09
Accepted
2016-05-09 16:37:20
Documents
46
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bind-10q_20160331.htm 10-Q 1488958
2 EX-31.1 bind-ex311_8.htm EX-31.1 18220
3 EX-32.1 bind-ex321_6.htm EX-32.1 7721
  Complete submission text file 0001564590-16-018603.txt   4166426

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT bind-20160331.xml EX-101.INS 742829
5 XBRL TAXONOMY EXTENSION SCHEMA bind-20160331.xsd EX-101.SCH 31032
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE bind-20160331_cal.xml EX-101.CAL 38008
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bind-20160331_def.xml EX-101.DEF 83810
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE bind-20160331_lab.xml EX-101.LAB 234503
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bind-20160331_pre.xml EX-101.PRE 173666
Mailing Address 325 VASSAR STREET CAMBRIDGE MA 02139
Business Address 325 VASSAR STREET CAMBRIDGE MA 02139 6174913400
BIND Therapeutics, Inc (Filer) CIK: 0001385228 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36072 | Film No.: 161632186
SIC: 2834 Pharmaceutical Preparations